Piergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, Laura Atzori, Anna Balato, Federico Bardazzi, Luca Bianchi, Angelo Cattaneo, Andrea Chiricozzi, Maurizio Congedo, Maria Concetta Fargnoli, Claudia Giofrè, Paolo Gisondi, Claudio Guarneri, Serena Lembo, Francesco Loconsole, Giampiero Mazzocchetti, Santo Raffaele Mercuri, Pietro Morrone, Anna Maria Offidani, Giovanni Palazzo, Aurora Parodi, Giovanni Pellacani, Stefano Piaserico, Concetta Potenza, Francesca Prignano, Marco Romanelli, Paola Savoia, Luca Stingeni, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Antonio Costanzo
{"title":"Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.","authors":"Piergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, Laura Atzori, Anna Balato, Federico Bardazzi, Luca Bianchi, Angelo Cattaneo, Andrea Chiricozzi, Maurizio Congedo, Maria Concetta Fargnoli, Claudia Giofrè, Paolo Gisondi, Claudio Guarneri, Serena Lembo, Francesco Loconsole, Giampiero Mazzocchetti, Santo Raffaele Mercuri, Pietro Morrone, Anna Maria Offidani, Giovanni Palazzo, Aurora Parodi, Giovanni Pellacani, Stefano Piaserico, Concetta Potenza, Francesca Prignano, Marco Romanelli, Paola Savoia, Luca Stingeni, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Antonio Costanzo","doi":"10.1007/s13555-024-01255-4","DOIUrl":null,"url":null,"abstract":"<p><p>Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2739-2757"},"PeriodicalIF":3.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480300/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-024-01255-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
